Sentence: In previous analyses of the MURANO study , fixed-duration venetoclax plus rituximab ( VenR ) resulted in improved progression-free survival ( PFS ) compared with bendamustine plus rituximab ( BR ) in patients with relapsed or refractory chronic lymphocytic leukemia ( CLL ) .
Drug combination annotation:
[{'class': 'POS', 'spans': ['venetoclax', 'rituximab'], 'is_context_needed': False}, {'class': 'COMB', 'spans': [2, 3], 'is_context_needed': True}]